share_log

C4 Therapeutics | 10-Q: Q1 2024 Earnings Report

C4 Therapeutics | 10-Q: Q1 2024 Earnings Report

C4 Therapeutics | 10-Q:2024财年一季报
美股SEC公告 ·  05/08 19:13

牛牛AI助手已提取核心信息

C4 Therapeutics (C4T) has reported significant developments in its collaboration agreements with Roche, Biogen, and Calico, focusing on the research, development, and commercialization of novel treatments using the company's proprietary TORPEDO platform. Under the amended Roche Agreement, C4T received an upfront payment of $40 million and may receive increased royalties and reimbursement for commercialization costs if it opts into co-development rights. Roche has the option to license and commercialize products for two targets, with potential milestone payments to C4T up to $273 million per target and sales-based milestone payments up to $150 million per target. The Biogen Agreement, which concluded its research term as of March 31, 2024, involved collaboration on treatments for neurological conditions. C4T received a $45 million upfront payment and is eligible for up to...Show More
C4 Therapeutics (C4T) has reported significant developments in its collaboration agreements with Roche, Biogen, and Calico, focusing on the research, development, and commercialization of novel treatments using the company's proprietary TORPEDO platform. Under the amended Roche Agreement, C4T received an upfront payment of $40 million and may receive increased royalties and reimbursement for commercialization costs if it opts into co-development rights. Roche has the option to license and commercialize products for two targets, with potential milestone payments to C4T up to $273 million per target and sales-based milestone payments up to $150 million per target. The Biogen Agreement, which concluded its research term as of March 31, 2024, involved collaboration on treatments for neurological conditions. C4T received a $45 million upfront payment and is eligible for up to $35 million per target in development milestones and $26 million per target in sales-based payments from Biogen. The Calico Agreement, which ended in March 2023, focused on diseases of aging, including cancer, with potential payments to C4T up to $132 million in development and commercial milestones per target, and up to $65 million in sales-based payments per target. Financially, C4T's revenue from collaboration agreements for the quarter ending March 31, 2024, was $3.039 million, a decrease from $3.759 million in the same period in 2023. The company's financial position includes $13.599 million in accounts receivable and $55.848 million in deferred revenue. C4T continues to advance its clinical trials, including its most advanced product candidates, cemsidomide (CFT7455) for multiple myeloma and non-Hodgkin lymphomas, and CFT1946 for BRAF V600X mutant solid tumors.
c4 therapeutics(C4T)宣布了与Roche、渤健公司和Calico的合作协议方面的重大进展,专注于使用公司专有的TORPEDO平台研究、开发和商业化创新疗法。根据修改后的Roche协议,C4万亿公司获得了一笔4000万美元的前期付款,如果选择合作开发权,则可能获得增加的版税和商业化成本补偿。Roche公司有选项对两个目标产品进行许可和商业化,每一目标的C4万亿公司可能获得高达2.73亿美元的里程碑付款和高达1.5亿美元的基于销售的里程碑付款。渤健公司协议的研究期在2024年3月31日结束,该协议涉及对神经疾病的治疗。C4万亿公司获得4500万美元的前期付款,并有资格从渤健公司在...展开全部
c4 therapeutics(C4T)宣布了与Roche、渤健公司和Calico的合作协议方面的重大进展,专注于使用公司专有的TORPEDO平台研究、开发和商业化创新疗法。根据修改后的Roche协议,C4万亿公司获得了一笔4000万美元的前期付款,如果选择合作开发权,则可能获得增加的版税和商业化成本补偿。Roche公司有选项对两个目标产品进行许可和商业化,每一目标的C4万亿公司可能获得高达2.73亿美元的里程碑付款和高达1.5亿美元的基于销售的里程碑付款。渤健公司协议的研究期在2024年3月31日结束,该协议涉及对神经疾病的治疗。C4万亿公司获得4500万美元的前期付款,并有资格从渤健公司在开发里程碑方面获得多达3500万美元的费用以及从销售中获得多达2600万美元的基于销售的支付费用。Calico公司在2023年3月结束的协议专注于老年疾病,包括癌症,C4万亿公司有可能获得高达1.32亿美元的每个目标的开发和商业里程碑费用,以及高达6500万美元的销售基础支付费用。财务方面,截至2024年3月31日的合作协议方面的C4T的营业收入为3039万美元,较2023年同期的3759万美元有所下降。公司的财务状况包括1.3599亿美元的应收账款和5584.8万美元的延期收入。C4万亿股份继续推进其临床试验,包括其最先进的产品候选人,即用于多发性骨髓瘤和非何杰金淋巴瘤的cemsidomide(CFT7455)以及用于BRAF V600X突变型实体瘤的CFT1946。

译文内容由第三方软件翻译。


牛牛AI助手部分由第三方人工智能模型基于资讯内容自动生成,只对中国内地以外的地区提供。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。